Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOLT-203 in Primary Hyperoxaluria Type 1
NCT06511349Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YOLT-203 in Primary Hyperoxaluria Type 1 (PH1), sponsored by Renji Hospital. Primary endpoint: Safety and Tolerability at 52 weeks. Started Jul 2024; status: recruiting.
02
Drugs
YOLT-203
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT06511349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511349.